Daprodustat for Dialysis CKD Anemia: HIF Mechanism, Thrombotic Black Box Warning, Blood Pressure and GI Monitoring

　　1.Position and Eligibility

　　Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stabilizes HIF and raises endogenous erythropoietin,increasing red cell production.

　　Use when all apply:

　　adult;

　　anemia due to chronic kidney disease;

　　receiving dialysis for at least 4 months;

　　other causes corrected or excluded:iron deficiency,vitamin deficiency,bleeding,chronic inflammation.

　　Not appropriate for:

　　non-dialysis CKD anemia;

　　urgent transfusion need;

　　“iron tonic”use;

　　uncontrolled hypertension or strong CYP2C8 inhibitor combination such as gemfibrozil.

　　2.Mechanism:Not Direct Iron

　　Daprodustat does not supply iron.It raises EPO so marrow uses available iron.Before start:

　　ferritin<100 ng/mL or TSAT<20%→supplemental iron;

　　most dialysis patients need iron support during therapy;

　　if anemia is from blood loss,inflammation,or nutrition,raising EPO alone fails.

　　Oral HIF-PHI differs from IV iron,but thrombotic logic resembles ESA:higher hemoglobin target increases risk.

　　3.Cardiovascular and Thrombotic Risk(Boxed Warning)

　　Label warns of increased death,myocardial infarction,stroke,venous thromboembolism,and vascular access thrombosis.

　　Higher-risk background:

　　prior CAD,MI,stroke,PAD;

　　heart failure history(more hospitalization);

　　prior access thrombosis;

　　uncontrolled or labile hypertension;

　　rapid/high hemoglobin rise;

　　smoking,hypercoagulable state,active cancer.

　　Rules:

　　do not target Hb>11 g/dL;

　　use lowest dose that reduces transfusion need;

　　dose changes no more often than every 4 weeks;

　　chest pain,dyspnea,sudden limb weakness,unilateral swelling/pain,speech disturbance→urgent care,not“anemia dizziness”.

　　4.Blood Pressure and Heart Failure

　　Uncontrolled hypertension is contraindicating.

　　Monitoring:

　　regular BP checks,adjust antihypertensives;

　　watch hypertensive crisis;

　　daily weight:rapid gain suggests fluid retention;

　　leg edema,orthopnea,reduced exercise tolerance→reassess heart failure;

　　prior HF needs nephrology+cardiology follow-up.

　　Hb trajectory matters:too fast a rise or sustained>11 g/dL prompts dose reduction;>12 g/dL usually holds therapy.

　　5.GI Erosion,Bleeding,Liver

　　Gastric/esophageal erosion and GI bleeding reported.

　　Higher risk:

　　peptic ulcer history;

　　prior GI bleed;

　　chronic NSAIDs/aspirin/steroids;

　　smoking/alcohol;

　　frailty.

　　Red flags:persistent abdominal pain,melena,hematemesis,coffee-ground vomit,pallor with dizziness.

　　Stop and seek care;do not wait.

　　Baseline LFTs:ALT,AST,ALP,bilirubin;repeat if symptoms or abnormal signals.

　　6.Malignancy and Avoidance

　　HIF pathways may unfavorably affect tumor growth;active malignancy not recommended.

　　Reassess benefit-risk in:

　　active cancer treatment;

　　severe liver disease;

　　non-dialysis CKD;

　　moderate–severe hepatic impairment;

　　strong CYP2C8 inhibitors(gemfibrozil contraindicated);clopidogrel needs starting-dose review.

　　7.Administration and Monitoring

　　oral once daily,with or without food,swallow whole;

　　missed dose same day,no double dose;

　　pre-treatment:anemia cause,iron,LFTs,BP,cardiac history;

　　first month after start/dose change:Hb every 2 weeks;

　　stable:Hb every 4 weeks;

　　each visit:BP,weight,access exam,iron indices;

　　GI history:watch stools/abdominal pain;

　　cardiac history:log chest pain/dyspnea/swelling.